IO Biotech Inc News - IOBT

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control...

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic...

Form 8-K - Current report

IO Biotech Reports 2024 Business Highlights

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and...

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of...

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and...

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04...

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09...

👍️0

glenn1919 5 days ago

IOBT..........................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783

👍️0

axelvento 1 month ago

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California.

https://www.stocktitan.net/news/IOBT/io-biotech-announces-new-preclinical-data-for-additional-pipeline-oc2de280qehy.html

https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Announces-New-Preclinical-Data-for-Additional-Pipeline-Candidate-Presented-at-the-AACR-IO-Conference/default.aspx

👍 1 🔜 1

ZLAZARUS 1 month ago

Wonderful day today! IOBT!

👍️0

ZLAZARUS 2 months ago

We are looking good here. Churning.

👍️0

ZLAZARUS 4 months ago

Ph3 melanoma data for IO102-IO103 remain on track for 1H25 and represents the next key catalyst. At .70 we are trading at cash. With a positive Ph3 melanoma readout we will be trading at $3.00 overnight with a march to $6.00 towards the later half of 2025. In addition, I'm encouraged by the supportive data in additional solid tumors which increases my confidence in the potential for success in the ongoing Ph3 melanoma study.

Also lets remember the IO102-IO103 melanoma study is with Merck's + pembrolizumab Ketruda. If IOBT's IO102-IO103 is approved, it will be a disruptive game changer thus creating an overnight valuation of about 200 million for the company in 2025. Leading into 2026, we could see a valuation conservatively of about $400M. This is my opinion.

👍️0

ZLAZARUS 4 months ago

Picked up at 20,000 shares @ .88 , I will pick up more when it drops below .73

👍️0

phrocks 4 months ago

Now you're a participant??

👍️0

ZLAZARUS 4 months ago

Targeting a fill between .70 & .78 Gem here on positive IOB-013/KN-D18 Q1 2025 Phase III results.

Monk are we finally on the move with this?

👍️0

axelvento 6 months ago

O Biotech is developing a cancer vaccine that targets both the tumor and its microenvironment - a pivotal readout is coming in the first half of next year
Founder and CEO Mai-Britt Zocca explains the rationale for this dual focus and walks us through the lead program that targets PD-L1 and IDO, and which has breakthrough therapy designation. A pivotal study in first line metastatic melanoma will read out soon.

https://www.biotechtv.com/post/io-biotech-october-11-2024

👍️0

Monksdream 6 months ago

IOBT under $2

👍️0

glenn1919 6 months ago

IOBT.................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783

👍️0

axelvento 6 months ago

IOBiotech
is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.

The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.

We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx

👍️0

glenn1919 6 months ago

iobt................................https://stockcharts.com/h-sc/ui?s=IOBT&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 7 months ago

IOBT new 52 week low
https://investorshub.advfn.com/uimage/uploads/2024/9/12/fmdniIMG_1694.gif

👍️0

Monksdream 7 months ago

IOBT under $2

👍️0

PonkenPlonken 8 months ago

starting to run into the readout
Lead investigator and advisors that helped BMS in making ipi+nivo the new SOC --- They now work on this. Cancer vaccines back in fashion.

👍️0

PonkenPlonken 8 months ago

Sorry for the late reply, im not yet fully familiar with this platform.
The SOC for advanced melanoma is Ipi + Nivo which is neither very helpful nor very safe. Hence "the bar is hanging low" here.

👍️0

Monksdream 8 months ago

IOBT

👍️0

stock1ace1 8 months ago

Standard of care …

👍️0

Monksdream 9 months ago

IOBT under $2

👍️0

ralfito 10 months ago

For us dummies, can you define SOC in this context? Thanks.

👍️0

PonkenPlonken 10 months ago

CEO made it pretty clear numerous times at Jefferies IMO
they will become the SOC, not only in advanced melanoma but in all stages.
They also think their platform can be used for non-cancer indications.

2 Birds in the hand and many more in the bush$$$

👍️0

PonkenPlonken 10 months ago

https://www.youtu be.com/watch?v=OvC-86SN9Ao&ab_channel=VJOncology

australian KOL on IOBT

many things pointing at it becoming the SOC one day...

👍️0

axelvento 10 months ago

golden cross MA50 MA200

👍️0

axelvento 10 months ago

a planned interim analysis of ORR will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024 and, if supportive, we believe could allow for submission of a BLA for accelerated approval in the US.
Cash and cash equivalents as of March 31, 2024 were $118.0 million, compared to $143.2 million at December 31, 2023. During the three months ended March 31, 2024, the company used cash, cash equivalents and restricted cash of $24.9 million. The increase in cash use was primarily driven by milestone payments and payment of other accrued expenses associated with clinical trials, as well as the payment of year-end bonuses. The company continues to expect that it will have sufficient cash to run the company into the fourth quarter of 2025.

👍️0

axelvento 11 months ago

Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
Progressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumors
Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025

https://www.biopharmcatalyst.com/company/IOBT/news/190095

👍️0

axelvento 11 months ago

https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Abstract-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting/default.aspx

👍️0

axelvento 12 months ago

IO Biotech was founded in 2014 and just 10 years into the journey we are in a pivotal phase III trial I think that’s quite fast

👍️0

axelvento 12 months ago

next catalyst-In November 2023, the company completed enrollment of 380 patients in its pivotal Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in advanced melanoma. The primary endpoint of the pivotal Phase 3 trial is progression free survival (PFS). The PFS analysis is event-driven and will be conducted when 226 events have occurred in the trial, which the company estimates will take place in the second half of 2025. Additionally, a planned interim analysis of overall response rate (ORR) will be conducted when the first 225 randomized patients reach one year of treatment in June 2024. The outcome of this analysis is expected in the third quarter of 2024.

👍️0

Monksdream 1 year ago

IOBT under $2

👍️0

Monksdream 1 year ago

IOBT under $2

👍️0

Monksdream 1 year ago

IOBT new 52 week low

👍️0

Monksdream 1 year ago

IOBT new 52 week low

👍️0

Monksdream 1 year ago

IOBT ubder $2

👍️0

AJ Freely 2 years ago

$IOBT - 👆Up 1.8% Pre-Market/ Current Price $2.00
Announces $75 Million Private Placement Financing

👍️0

The Night Stalker 2 years ago

nice

👍️0

kzivann 2 years ago

Extremely heavy volume on good news. PPS down . Lower this AM. Watching

IOBT

👍️0

Phosphene 3 years ago

IO Biotech’s (NASDAQ:IOBT ) lock-up period is set to end on Wednesday, May 4th.

https://www.defenseworld.net/2022/04/27/io-biotech-inc-s-lock-up-period-set-to-end-on-may-4th-nasdaqiobt.html

👍️0

conix 3 years ago

Bitoechs are waking up ---like they did last year.

I shopped for a number of sold out biotechs in December and picked and chose a number of sold out biotechs.

IOBT --I missed. But there are legs here. I have done well on four of my picks. Still waiting on two.

Time will tell.

👍️0

Phosphene 3 years ago

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

IO Biotech to initiate a Phase 2 combination trial to explore safety and efficacy for treating multiple tumor types

https://www.globenewswire.com/news-release/2021/12/06/2346557/0/en/IO-Biotech-Announces-Third-Clinical-Collaboration-with-Merck-to-Evaluate-IO102-IO103-in-Combination-With-KEYTRUDA-pembrolizumab-as-First-Line-Treatment-in-a-Phase-2-Multi-Arm-Baske.html

👍️0

Eggplant 3 years ago

What happened? IPO at $14/sh four weeks ago, and the stock has nearly folded in half. No news, and the only sellers should be the IPO buyers, right? Mystery.

👍️0

Work Harder 3 years ago

I was right on the 7

for now

Yu tell wifeie

I appreciate her time

:}

👍️0

Phosphene 3 years ago

Did Sunstone/Verland recoup initial seed?

👍️0

Staypositive1 3 years ago

might wait till .035...lol

👍️0

Phosphene 3 years ago

IO Biotech begins trading on Nasdaq Global Market today.

IPO pps is $14.

Thu, November 4, 2021, 11:52 PM.

https://finance.yahoo.com/news/io-biotech-inc-announces-pricing-035200314.html?fr=sycsrp_catchall

Sunstone and Novo Holdings involved.

👍️0

Phosphene 3 years ago

EXPLORATORY PROJECT TO COMPARE IO BIOTECH ANTIGENS LINKED TO MYMETICS’ (MYMX) VIROSOMES IN A PRECLINICAL TUMOR MODEL

https://www.mymetics.com/media-center/exploratory-project-compare-io-biotech-antigens-linked-mymetics-virosomes-preclinical-tumor-model/

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

https://www.prnewswire.com/news-releases/io-biotech-announces-clinical-collaboration-with-msd-to-evaluate-io102-io103-with-keytruda-pembrolizumab-as-first-line-treatment-in-metastatic-melanoma-patients-in-a-phase-3-trial-301375679.html

👍️0

Phosphene 3 years ago

Denmark's IO Biotech seeks $110M+ in Nasdaq debut.

https://pitchbook.com/newsletter/denmarks-io-biotech-seeks-110m-in-nasdaq-debut

https://www.fiercebiotech.com/biotech/io-biotech-raises-155m-to-trial-ido-and-pd-l1-cancer-vaccines

https://www.iobiotech.com/

The Food and Drug Administration (FDA) grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/ metastatic melanoma

https://www.firstwordpharma.com/node/1783725?tsid=17

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

IO Biotech Inc (IOBT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

IOBT News

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

Form 8-K - Current report

IO Biotech Reports 2024 Business Highlights

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Form 8-K - Current report

IOBT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

IO Biotech Inc (IOBT) News

IO Biotech Inc (IOBT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

IOBT News

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025

Form 8-K - Current report

IO Biotech Reports 2024 Business Highlights

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Form 8-K - Current report

IOBT Discussion

Your Recent History

Go Ad-Free